We are developing treatments for intractable neuromuscular diseases by applying vector-based technology to gene and cell therapies. To develop an effective treatment for Duchenne muscular dystrophy, for which there is no definitive treatment, we are verifying the safety and efficacy of the delivery of micro-dystrophin, and methods for the sustainable gene expression and induction of immune tolerance using mouse and dog disease model animals as well as primates.